1 completed, 1 terminated, 1 withdrawn. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Decitabine (DAC): new trials by email Literature Review of Decitabine (DAC) trials Research Report on Decitabine (DAC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab - Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2018-04-11 | 2023-05-31 |
| Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy decitabine (DAC), Tetrahydrouridine (THU), Celecoxib - Neoplasm Metastasis, Sarcoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-07-07 | 2018-07-05 | |
| Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia Filgrastim, Busulfan, Cyclophosphamide - Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 1995-08-01 | 2018-10-26 |
Blast Crisis (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Neoplasms, Germ Cell and Embryonal (1) · Sarcoma (1)
National Cancer Institute (NCI) (2) · M.D. Anderson Cancer Center (1)
United States (2)
David S Schrump, M.D. (2) · Sergio Giralt, MD (1)
P30CA016672 (1)